This review highlights the electrophysiological immaturity of stem cell-derived cardiomyocytes as a major hurdle for safe cell-based myocardial repair due to proarrhythmic risks.
No takes yet. Share an insight, caveat, or question.
Requires caution in cell therapy trials due to proarrhythmia risk; leaves open whether maturation strategies can enable safe translation.
Chen et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: